HHS Seeks Early Win Defending Medicare Drug Price Program

By Dan McKay · December 21, 2023, 7:24 PM EST

Boehringer Ingelheim and other drugmakers are free to take their business elsewhere if they object to the new Medicare price negotiation program, the federal government has said, urging a judge to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

Case Number

3:23-cv-01103

Court

Connecticut

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 18, 2023

Recent Articles By Dan

November 19, 2024
No 'Tin Hats': Fluoride Ruling Offers Options As RFK Eyes Ban
November 15, 2024
Teva Defends Mifepristone Antitrust Case Against Corcept
November 12, 2024
Wash. Ballot Win Gives States Blueprint For 'Age Wave' Care
November 06, 2024
Voters Pass Medicaid Tax In Calif., Support IVF Coverage In Ill.
November 05, 2024
Biotech, Pharma Cos. Eye Impact Of DOJ's Foreign Data Rule
October 31, 2024
Beverly Hills Agrees To Abortion-Rights Training In Settlement
October 29, 2024
4th Circ. Quizzes Drugmaker Challenging W.Va. Abortion Law
October 29, 2024
Beyond Abortion, 7 Ballot Questions Set To Shape Care
October 23, 2024
NC Justices Scrutinize Scope Of Liability Shield In COVID Law
October 22, 2024
Drug-Shortage List Under Scrutiny After FDA Reversal